<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3838">
  <stage>Registered</stage>
  <submitdate>19/09/2012</submitdate>
  <approvaldate>19/09/2012</approvaldate>
  <nctid>NCT01705080</nctid>
  <trial_identification>
    <studytitle>IntErnational Long-term Follow-up Study of Patients With Uncontrolled HyperTensioN</studytitle>
    <scientifictitle>IntErnational Non-randomized, Single-arm, Long-term Follow-up Study of Patients With Uncontrolled HyperTensioN</scientifictitle>
    <utrn />
    <trialacronym>EnligHTN-II</trialacronym>
    <secondaryid>1201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypertension</healthcondition>
    <healthcondition>Blood Pressure</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - EnligHTN

A - EnligHTN for Severe Resistant HTN - Office systolic Blood Pressure =160 mmHg
Subject is taking =3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Patient has an estimated GFR =45 mL/min per 1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula

B - EnligHTN for Resistant HTN - Office systolic Blood Pressure =140 mmHg
Subject is taking =3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Patient has an estimated GFR =45 mL/min per 1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula

C - EnligHTN for Resistant HTN &amp; CKD - Office systolic Blood Pressure =140 mmHg
Subject is taking =3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
Patient has an estimated =15 GFR &lt;45 mL/min per 1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula


Treatment: devices: EnligHTN
Renal artery ablation with EnligHTN system used for all groups

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome> Mean reduction in office Systolic Blood Pressure at six (6) months across all subjects post renal denervation and within sub-groups</outcome>
      <timepoint>6 months post procedure</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percent of patients who experience a procedural related event</outcome>
      <timepoint>30 days post procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of renovascular safety as measured by new renal artery stenosis or aneurysm at the site of ablation</outcome>
      <timepoint>6 months, 2 years, and 5 years post procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Renal function change based on eGFR</outcome>
      <timepoint>6 months, 2 years, and 5 years post procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Ambulatory Blood Pressure parameters at 6 months</outcome>
      <timepoint>6 months post procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in office Diastolic Blood Pressure at 6 months</outcome>
      <timepoint>6 months post procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of subjects achieving office Systolic Blood Pressure &lt; 140 at 6 month visit</outcome>
      <timepoint>6 months post procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Office Blood Pressure parameters at 12, 24, 36, 48, 60 months post denervation</outcome>
      <timepoint>12, 24, 36, 48, 60 months post procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Ambulatory Blood Pressure parameters at 12, 24, 36, 48, 60 months post denervation</outcome>
      <timepoint>12, 24, 36, 48, 60 months post procedure</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subject is = 18 years of age at time of consent

          -  Subject must be able and willing to provide written informed consent

          -  Subject must be able and willing to comply with the required follow-up schedule

          -  Subject has office Systolic Blood Pressure = 140 mmHg at confirmatory visit

          -  Subject has a daytime mean Systolic Ambulatory Blood Pressure &gt; 135 mmHg within 90
             days prior to procedure

          -  Subject has established hypertension (diagnosed =12 month prior to baseline) and on a
             guideline based drug regimen at a stable and fully tolerated dose consisting of = 3
             anti-hypertensive medications (including 1 diuretic) or subject has a documented drug
             intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB,
             Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3
             anti-hypertensive drugs.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subject has significant renovascular abnormalities such as renal artery stenosis &gt; 30%

          -  Subject has undergone prior renal angioplasty, renal denervation, indwelling renal
             stents, and/or abdominal aortic stent grafts

          -  Subject has hemodynamically significant valvular heart disease as determined by study
             investigator

          -  Subject has a life expectancy less than 12 months, as determined by the Investigator

          -  Subject is participating in another clinical study which has the potential to impact
             their hypertension management (pharmaceutical/device/homeopathic)

          -  Subject is pregnant, nursing, or of childbearing potential and is not using adequate
             contraceptive methods

          -  Subject has active systemic infection

          -  Subject has renal arteries with diameter(s) &lt; 4 mm in diameter

          -  Subject has an estimated GFR &lt;15 mL/min per 1.73 m2 using the Modification of Diet in
             Renal Disease (MDRD) formula

          -  Subject had a renal transplant or is awaiting a renal transplant

          -  Subject has blood clotting abnormalities</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>354</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/05/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>The Prince Charles Hospital - Chermside</hospital>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - Chermside</postcode>
    <postcode> - Parkville</postcode>
    <postcode> - Perth</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Innsbruck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Tampere</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Besancon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>St. Etienne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Strasbourg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Nordrhein Westfalen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Krozingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Nauheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Coburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Homburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ingolstadt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Trier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Den Haag</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Dunedin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Bergen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Trondheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Basque</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Goteborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sheffield</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>St. Jude Medical</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this post market clinical investigation is to further evaluate the safety and
      performance of the EnligHTN Renal Denervation System in the treatment of patients with
      uncontrolled hypertension.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01705080</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Melvin Lobo, MD</name>
      <address>NIHR Barts Cardiovascular Biomedical Research Unit</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>